Healthcare Cost, Quality, and Outcomes:
ISPOR Book of Terms
Coming Soon! ISPOR Book of Terms 2020
ISPOR is revising its seminal Healthcare Cost, Quality and Outcomes: ISPOR Book of Terms.
Be a contributor! Click here and volunteer today!
ISPOR Book of Terms 2020 will include more than 500 terms used in healthcare delivery, management, and regulation, as well as healthcare outcomes research including clinical, economic, and quality-of-life research terms.
Each monograph will include a key term and a listing of related terms described in the monograph, a brief definition of the term, explanation and usage of the term (and related terms), the value of the term(s), key issues, related ISPOR resources, such as ISPOR Good Practices Task Force and Special Interest Group Reports and 5 references as well as selected figures, tables, and graphs.
This book will facilitate greater understanding of health economics and outcomes research (HEOR) and its use in healthcare decisions. The target audience includes: decision makers, students, new professionals in the HEOR field, payers, clinicians, patient representatives, etc. Readers represent a global audience.
Each monograph includes an important term and a listing of related terms described in the monograph, a brief definition of the key term, an explanation of the use of the key term (and related terms), the value of the term(s), key issues, and 3 to 5 references as well as selected figures, tables, and graphs.
In the previous version, more than 200 ISPOR members contributed to this book, both as authors and reviewers. Listed below are just some of the 100+ monographs that will be included in the ISPOR Book of Terms 2020.
Bayesian Analysis | Bootstrapping | Cost Effective Analysis | Cost Minimization Analysis | Decision Tree | Disability Adjusted Life Year | Disease Management | Drug Pricing | Drug Safety | Drug Use Evaluation | Epidemiology | Evidence Based Medicine | Gene Therapy | Health State Utilities | Health Years Equivalent | Likelihood Ratio | Medical Device | Modeling | Multi Criteria Decision Analysis (MCDA) | Net Benefit | Optimization | Number Needed to Treat | Simulation Modeling | Uncertainty | Value of Information
Marc L. Berger MD, Vice President, Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN, USA
Kerstin Bingefors PhD, MSc, Associate Professor, Biomedical Centre, Uppsala University, Dept of Pharmacy; Pharmacoepidemiology and PE, Uppsala, Sweden
Edwin Hedblom PharmD, Manager, Clinical Research & Discovery Center, 3M Medical, St. Paul, MN, USA
Chris L. Pashos PhD, Vice President and Executive Director, Abt Bio-Pharma Solutions, Inc. - HERQuLES, Lexington, KY, USA
George Torrance PhD, Professor Emeritus, McMaster University, Principal Consultant, i3 Innovus, Toronto, ON, Canada
Marilyn Dix Smith RPh, PhD, Founding Executive Director, ISPOR, Lawrenceville, NJ, USA
Berger ML, Bingefors K, Hedblom EC, Pashos CL, Torrance GW. Health Care Cost, Quality, and Outcomes: ISPOR Book of Terms. Lawrenceville, NJ: ISPOR, 2003.